Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Stryker Corp (NY:SYK)

377.79 -14.94 (-3.80%)
Official Closing Price Updated: 7:00 PM EDT, Aug 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Stryker Corp

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Q4 Earnings Review: Medical Devices & Supplies - Diversified Stocks Led by Boston Scientific (NYSE:BSX)
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Boston Scientific (NYSE:BSX) and the best... 
Via StockStory
Jim Cramer: This Health Care Stock Is A 'Winner,' Buy Bitcoin Instead Of Coinbase
On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying AbbVie Inc. (NYSE:ABBV), saying it's “just a gem” and a “winner.”  He added, “I can't believe the stock dropped so much.” 
Via Benzinga
Stryker declares an $0.84 per share quarterly dividend
From Stryker Corporation
Via GlobeNewswire
$100 Invested In Stryker 10 Years Ago Would Be Worth This Much Today
 
Via Benzinga
A Glimpse Into The Expert Outlook On Stryker Through 14 Analysts
 
Via Benzinga
Stryker Earnings Report: Q4 Overview
 
Via Benzinga
Stryker Earnings Review: Q4 Summary
 
Via Benzinga
Stryker (NYSE:SYK) Posts Better-Than-Expected Sales In Q4
Medical technology company Stryker (NYSE:SYK) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 10.7% year on year to $6.44 billion. Its non-GAAP profit of $4.01 per... 
Via StockStory
Stryker's Strategic Moves Impress Analysts, Spine Implant Sale and NARI Deal Set to Drive Future Growth
Wall Street analysts upgraded Stryker Corp (NYSE: SYK) after its Q4 report beat expectations, with strong sales and earnings growth projected for 2025. 
Via Benzinga
Starbucks To Rally Over 23%? Here Are 10 Top Analyst Forecasts For Wednesday
 
Via Benzinga
US Futures Point To Cautious Start As Investors Await Fed's Rate Decision: Tesla, Microsoft, Meta Among Stocks In Focus Ahead Of Earnings
U.S. stock futures were mixed ahead of the crucial earnings from key U.S. technology companies and the Fed's expected pause on rate cuts. 
Via Benzinga
Topics Economy
Stryker Earnings Analysis: Q4 Recap
 
Via Benzinga
Stryker Q4 Earnings Assessment
 
Via Benzinga
Insights into Stryker Q4 Earnings
 
Via Benzinga
Tesla, Starbucks And 3 Stocks To Watch Heading Into Wednesday
 
Via Benzinga
Stryker Undercuts Breakout On Sales Deal, Despite Quarterly Beat
Stryker stock dipped late Tuesday after the medtech company beat forecasts, but announced its plan to divest the U.S. spinal business. 
Via Investor's Business Daily
Earnings Summary: Stryker Q4
 
Via Benzinga
Stryker announces the retirement of Glenn S. Boehnlein and the promotion of Preston Wells to Vice President, Chief Financial Officer
From Stryker Corporation
Via GlobeNewswire
Stryker announces definitive agreement for the sale of its U.S. spinal implants business and plans to sell related international business
From Stryker Corporation
Via GlobeNewswire
If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today
 
Via Benzinga
How Is The Market Feeling About Stryker?
 
Via Benzinga
Stryker reports 2024 operating results and 2025 outlook
From Stryker Corporation
Via GlobeNewswire
Earnings Scheduled For January 28, 2025
 
Via Benzinga
Stryker commences tender offer for all outstanding shares of common stock of Inari Medical, Inc.
From Stryker Corporation
Via GlobeNewswire
Stryker Had A Good Year Last Year; Here's How It's Looking For 2025
Reflecting its strong growth, on Monday the Relative Strength (RS) Rating for Stryker stock got an upgrade from 70 to 74. 
Via Investor's Business Daily
Plug Power, Capri And Frontline Are Among Top Mid Cap Gainers Last Week (Jan 6-10): Are The Others In Your Portfolio?
These mid-cap stocks had impressive gains last week, including Inari Medical, Unifirst Corporation, and Walgreens. Are they in your portfolio? 
Via Benzinga
Stryker To Buy Inari Medical In $5 Billion Deal To Bolster Venous Thromboembolism Position
Stryker acquires Inari Medical in a $4.9 billion deal, enhancing its vascular portfolio with innovative VTE treatments and a growing global reach. 
Via Benzinga
Why Inari Medical Shares Are Trading Higher By 21%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Stryker announces definitive agreement to acquire Inari Medical, Inc., providing entry into high-growth peripheral vascular segment
From Stryker Corporation
Via GlobeNewswire
Inari Medical Catapults 30% On Rumored Stryker Takeover
Inari is best-known for its series of catheter-like devices that remove blood clots. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.